Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects

ClinicalTrials.gov ID: NCT01011959

Public ClinicalTrials.gov record NCT01011959. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 10, 2026, 12:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Parallel-group Study of the Safety and Tolerability of REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized study of the safety and tolerability of multiple doses of REGN88 in rheumatoid arthritis patients who are receiving treatment with methotrexate.

Study identification

NCT ID
NCT01011959
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
60 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2008
Primary completion
Jul 31, 2009
Completion
Jul 31, 2009
Last update posted
Sep 29, 2013

2008 – 2009

United States locations

U.S. sites
24
U.S. states
15
U.S. cities
24
Facility City State ZIP Site status
Not listed Santa Maria California
Not listed Boca Raton Florida
Not listed Clearwater Florida
Not listed Daytona Beach Florida
Not listed Delray Beach Florida
Not listed Palm Harbor Florida
Not listed Idaho Falls Idaho
Not listed Worcester Massachusetts
Not listed Lansing Michigan
Not listed Flowood Mississippi
Not listed Kalamzaoo Missouri
Not listed St Louis Missouri
Not listed Reno Nevada
Not listed Charlotte North Carolina
Not listed Cincinnati Ohio
Not listed Toledo Ohio
Not listed Oklahoma City Oklahoma
Not listed Duncansville Pennsylvania
Not listed Greenville South Carolina
Not listed Orangeburg South Carolina
Not listed Hixson Tennessee
Not listed Austin Texas
Not listed Houston Texas
Not listed San Antonio Texas

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01011959, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 29, 2013 · Synced Sep 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01011959 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →